GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.

Sawicka-Gutaj N, Gruszczyński D, Nijakowski K, Derwich-Rudowicz A, Krenz M, Kumar A, Lu PY, Ruchała M

International journal of obesity (2005)25 Apr 2026Cited by 5 (Europe PMC)

PMID42034831PMCIDPMC13461353DOI10.1038/s41366-026-02088-1PepBankPUB-42034831

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study26

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone26

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that body weight consistently fell across time points.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed body weight consistently fell across time points.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483101
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that body weight consistently fell across time points.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed body weight consistently fell across time points.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483102
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that BMI consistently fell across time points.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed BMI consistently fell across time points.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483103
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that BMI consistently fell across time points.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed BMI consistently fell across time points.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483104
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that waist circumference consistently fell across time points.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed waist circumference consistently fell across time points.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483105
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that waist circumference consistently fell across time points.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed waist circumference consistently fell across time points.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483106
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that mean body weight fell about 9% at 3 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed mean body weight fell about 9% at 3 months.
Peptide
Semaglutide
Outcome
DecreaseMean body weight at 3 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
mean body weight decrease
≈ 9%
3 months
Source sentences
Summary
At 3 months, mean body weight decreased by approximately 9%, accompanied by marked reductions in fat mass and visceral adipose tissue.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483107
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that mean body weight fell about 9% at 3 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed mean body weight fell about 9% at 3 months.
Peptide
Liraglutide
Outcome
DecreaseMean body weight at 3 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
mean body weight decrease
≈ 9%
3 months
Source sentences
Summary
At 3 months, mean body weight decreased by approximately 9%, accompanied by marked reductions in fat mass and visceral adipose tissue.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483108
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that fat mass fell at 3 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed fat mass fell at 3 months.
Peptide
Semaglutide
Outcome
DecreaseFat mass at 3 months
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 3 months, mean body weight decreased by approximately 9%, accompanied by marked reductions in fat mass and visceral adipose tissue.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483109
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that fat mass fell at 3 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed fat mass fell at 3 months.
Peptide
Liraglutide
Outcome
DecreaseFat mass at 3 months
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 3 months, mean body weight decreased by approximately 9%, accompanied by marked reductions in fat mass and visceral adipose tissue.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483110
11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that visceral fat fell at 3 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed visceral fat fell at 3 months.
Peptide
Semaglutide
Outcome
DecreaseVisceral adipose tissue at 3 months
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 3 months, mean body weight decreased by approximately 9%, accompanied by marked reductions in fat mass and visceral adipose tissue.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483111
12HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that visceral fat fell at 3 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed visceral fat fell at 3 months.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue at 3 months
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 3 months, mean body weight decreased by approximately 9%, accompanied by marked reductions in fat mass and visceral adipose tissue.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483112
13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that lean mass was largely preserved at 6 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed lean mass was largely preserved at 6 months.
Peptide
Semaglutide
Outcome
Not applicableLean mass at 6 months
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
4 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483113
14HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that lean mass was largely preserved at 6 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed lean mass was largely preserved at 6 months.
Peptide
Liraglutide
Outcome
Not applicableLean mass at 6 months
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
4 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483114
15HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that weight loss persisted at about 4% at 12 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed weight loss persisted at about 4% at 12 months.
Peptide
Semaglutide
Outcome
DecreaseWeight loss at 12 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
weight loss
≈ 4%
12 months
Source sentences
Summary
At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483115
16HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that weight loss persisted at about 4% at 12 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed weight loss persisted at about 4% at 12 months.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 12 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
weight loss
≈ 4%
12 months
Source sentences
Summary
At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483116
17HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that fat-mass decline predominated over modest lean-mass reductions.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed fat-mass decline predominated over modest lean-mass reductions.
Peptide
Semaglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483117
18HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that fat-mass decline predominated over modest lean-mass reductions.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed fat-mass decline predominated over modest lean-mass reductions.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483118
19HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that lean-body-mass reductions were modest.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed lean-body-mass reductions were modest.
Peptide
Semaglutide
Outcome
DecreaseLean body mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483119
20HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that lean-body-mass reductions were modest.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed lean-body-mass reductions were modest.
Peptide
Liraglutide
Outcome
DecreaseLean body mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483120
21HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that weight reduction averaged 5% at 6 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed weight reduction averaged 5% at 6 months.
Peptide
Semaglutide
Outcome
DecreaseWeight reduction at 6 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
weight reduction
5%
6 months
Source sentences
Summary
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
4 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483121
22HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that weight reduction averaged 5% at 6 months.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed weight reduction averaged 5% at 6 months.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction at 6 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
weight reduction
5%
6 months
Source sentences
Summary
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
4 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483122
23HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that 6-month weight reductions were comparable across semaglutide, liraglutide and exenatide.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed 6-month weight reductions were comparable across semaglutide, liraglutide and exenatide.
Peptide
Semaglutide
Outcome
Not applicableComparable weight-reduction effects at 6 months
Study
n: not reported in source
Comparator
Semaglutide, liraglutide and exenatide
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
4 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483123
24HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that 6-month weight reductions were comparable across semaglutide, liraglutide and exenatide.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed 6-month weight reductions were comparable across semaglutide, liraglutide and exenatide.
Peptide
Liraglutide
Outcome
Not applicableComparable weight-reduction effects at 6 months
Study
n: not reported in source
Comparator
Semaglutide, liraglutide and exenatide
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
4 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483124
25HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that 12-month weight loss varied between agents, notably liraglutide.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed 12-month weight loss varied between agents, notably liraglutide.
Peptide
Semaglutide
Outcome
Direction not reportedVariability in weight loss between agents at 12 months
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4203483125
26HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1-based therapy findings showed that 12-month weight loss varied between agents, notably liraglutide.
In plain wordsIn adults with overweight or obesity, pooled GLP-1 findings showed 12-month weight loss varied between agents, notably liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedVariability in weight loss between agents at 12 months
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide.
5 context sentences(design, population, supporting numbers)
Title · context
GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Summary · context
The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus.
Summary · context
A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines.
Summary · context
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months).
Summary · context
At 6 months, weight reduction averaged 5%, with semaglutide, liraglutide, and exenatide showing comparable effects, while lean mass remained largely preserved.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4203483126

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.

Summary

Results from this study26

Studies that did not test the peptide alone26

Version history

Subjects

Publication types

MeSH terms